Le Lézard
Classified in: Health, Science and technology
Subject: Product/Service

Veristat Announces Global Cell and Gene Therapy Center of Excellence


Cell and gene therapies represent the next great wave of therapeutic innovation and have led to the development of promising therapies worldwide.

Veristat, a scientific minded clinical research organization, announced today the launch of their Global Cell and Gene Therapy Center of Excellence (COE). The COE comprises a multi-disciplinary team of scientific experts who are adept at strategy and execution across this complex clinical development pathway. Veristat's experience supporting these unique programs in the Americas and Europe enables them to implement impactful advisory and tactical services to support the challenging decisions required to advance a cell and gene therapy to market. Leveraging the learnings from the support of numerous client cell and gene therapy programs, including the first gene therapy approved in Europe, the Global COE will serve as a powerhouse for sponsors and as a mechanism to share insights, successful strategies, and best practices.

"We understand how high the stakes are with cell and gene therapy programs," stated Alecia Barbee, Executive Vice President, Operations at Veristat, "and that nothing is standard about the therapies, the studies or the regulatory processes in this specialized area. Veristat has successfully supported more than 100 cell and gene therapy projects across the entire clinical development life-cycle, and with the launch of our center of excellence, we are formalizing our processes to assist sponsors around the globe to bring these advanced therapies to market quickly."

Every cell or gene therapy is unique, often coming with a complicated regulatory approval process and unique therapeutic challenges. Even the best therapeutic may not reach patients who need it if the study design and execution are not optimal. Veristat offers tailored solutions across the entire clinical development pathway to combat these challenges, including:

"The challenges of developing cell and gene therapies requires a committed and experienced partner," stated Patrick Flanagan, Chief Executive Officer at Veristat. "Cell and gene therapies offer uniquely curative potential for disorders that are intractable to other treatment modalities. They can save lives. The challenge now is to scale the opportunity they offer to their full potential. Our years of experience in this specialized area and reputation for success will make Veristat the CRO of choice for small and medium biopharmaceutical companies who want to bring their cell or gene therapies to patients worldwide."

About Veristat:

Veristat, a scientific-minded global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 26 years' experience in clinical trial planning and execution, Veristat is equipped to support any development program. Our team has prepared nearly 100 marketing applications for approval with global regulatory authorities in the last ten years.

Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, advanced therapies, oncology, and infectious disease trials. We apply this knowledge base every day to solve any clinical program's challenges, from the simplest to the complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving lives. For more information, visit www.veristat.com.


These press releases may also interest you

at 17:40
VerticalScope Holdings Inc. ("VerticalScope"), a technology company that has built and operates a cloud-based digital platform for online enthusiast communities with 65 million registered users, today announced it has adopted The Trade Desk's...

at 17:35
Overcoming the longs odds of a life prison sentence, a year in solitary confinement, generational drug addiction and gang involvement 10 former felons who collectively served more than 100 years this week shared their journeys from incarceration to...

at 17:25
Myomo, Inc. ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the...

at 17:23
EVP Capital Inc. ("EVP Capital"), a capital pool company ("CPC") listed on the TSX Venture Exchange Inc. (the "Exchange"), is pleased to announce that it has entered into a non-binding letter of intent dated May 1, 2024 (the "LOI") with Sharp Edge...

at 17:20
SnapLogic, the leader in generative integration, today announced that it has been positioned by Aragon Research, Inc. as a Leader in the third annual Globetm for Transformation Platform as a Service. Download a complimentary copy of The Aragon...

at 17:15
Robert Half Inc. announced today that its board of directors has approved a quarterly cash dividend of $0.53 per share. The cash dividend will be paid June 14, 2024, to all shareholders of record as of May 24, 2024....



News published on and distributed by: